GLP-1 drug interactions

GLP-1 Drug Interaction Checker

Look up any medication against Foundayo, Mounjaro, Zepbound, Ozempic or Wegovy. Each entry carries a severity tier and names its source: the FDA prescribing-information section where a label covers it, or the study or review where none does. The database holds 18 interactions at present.

Filter by severity

18 of 18 entries shown, each one citing the FDA prescribing information section it came from. This is educational material and replaces neither pharmacist nor prescriber.

Interaction results

Other GLP-1 receptor agonists

GLP-1 receptor agonist

Serious — close monitoring

Common brand names

Wegovy · Ozempic · Rybelsus · Zepbound · Mounjaro · Foundayo · Saxenda · Victoza · Trulicity · Bydureon · Byetta

Clinical effect

Section 1 (Limitations of Use) of the Wegovy, Zepbound and Foundayo labels each advise against pairing the drug with a second GLP-1 receptor agonist (their wording: "not recommended"). The Ozempic and Mounjaro labels carry no such sentence, but there is no clinical case for stacking two drugs aimed at the same receptor, and what stacks up if you try it — GI side effects, and hypoglycemia where T2D is present — argues against it.

What to do

Never run the two together. To change drugs, stop the first and begin the second at its lowest dose on what would have been the next injection day — that is the ordinary switching guidance used in practice. A full pharmacokinetic washout is a separate matter: it lasts 5 half-lives, roughly 25 days for tirzepatide, roughly 35 days for semaglutide. Our washout calculator at /tools/glp1-washout-calculator uses those figures, because planning around surgery or pregnancy is a different question from switching drugs.

Mechanism

One receptor, two drugs aimed at it. Nothing extra is gained in efficacy; what doubles is receptor activation, and with it the side effects.

Source: Wegovy PI Section 1 (Limitations of Use): "Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended." Zepbound PI Section 1: "Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended." Foundayo PI Section 1: "Concomitant use with another GLP-1 receptor agonist is not recommended."

Insulin

Insulin (long, intermediate, or rapid acting)

Serious — close monitoring

Common brand names

Lantus · Toujeo · Basaglar · Tresiba · Levemir · Humalog · Novolog · Apidra · Fiasp · Lyumjev · Humulin · Novolin

Clinical effect

Insulin taken alongside a GLP-1 receptor agonist makes hypoglycemia — blood sugar falling too low — more likely, and the escalation weeks are when it is likeliest.

What to do

Each of the five labels tells prescribers to weigh a lower insulin or secretagogue dose at the point the GLP-1 begins ("consider reducing the dose"), so that blood sugar is less likely to crash. The labels give no fixed percentage, so how much is your prescriber's call. Agree it with them BEFORE the first GLP-1 dose, and watch blood glucose closely from there. The Wegovy label adds that Wegovy in combination with insulin "has not been evaluated".

Mechanism

A GLP-1 receptor agonist already pushes insulin secretion up in a glucose-dependent way while pulling glucagon down. Injected insulin lands on top of that, and the hypoglycemic risk adds together.

Source: Wegovy PI Section 7.1; Ozempic PI Section 7.1; Mounjaro PI Section 7.1; Zepbound PI Section 7.1; Foundayo PI Section 7.2

Sulfonylureas

Sulfonylurea (oral diabetes medication)

Serious — close monitoring

Common brand names

Glucotrol · glipizide · DiaBeta · Glynase · Micronase · glyburide · Amaryl · glimepiride

Clinical effect

Put a sulfonylurea together with a GLP-1 receptor agonist and hypoglycemia becomes substantially more likely.

What to do

On a sulfonylurea — glimepiride, glyburide, glipizide — expect your prescriber to cut that dose as the GLP-1 begins. Some people come off the sulfonylurea altogether. Either way, keep a close watch on blood glucose.

Mechanism

A sulfonylurea drives insulin out whatever the glucose level happens to be. The GLP-1 then adds its own glucose-dependent boost. In the labeled trials, hypoglycemia (below 54 mg/dL) struck 10.3% of Zepbound users who also took a sulfonylurea, against 2.1% of Zepbound users without one (Zepbound PI 5.7), and in 7% versus 0.5% on Foundayo (Foundayo PI 5.5).

Source: Wegovy PI Section 7.1; Ozempic PI Section 7.1; Mounjaro PI Section 7.1; Zepbound PI Sections 7.1 and 5.7; Foundayo PI Sections 7.2 and 5.5 (insulin secretagogues)

CYP3A4 inhibitors and inducers (Foundayo only)

CYP3A4 inhibitor or inducer

Serious — close monitoring

Common brand names

ketoconazole · itraconazole · clarithromycin · ritonavir · cobicistat · rifampin · rifampicin · carbamazepine · phenytoin · St. John's Wort · efavirenz

Clinical effect

FOUNDAYO (orforglipron) alone is affected here; the Wegovy, Ozempic, Mounjaro and Zepbound labels set no CYP3A4 rule. Because CYP3A4 metabolizes Foundayo, a strong inhibitor of that enzyme pushes Foundayo levels up (clarithromycin raised Foundayo AUC 3.5-fold in the labeled study), and a strong inducer can pull them down far enough to cost you the effect (carbamazepine cut AUC by 82%).

What to do

The Foundayo label sets four rules. With a strong CYP3A4 inhibitor (the label's studied example is clarithromycin), "The maximum dosage of FOUNDAYO is 9 mg once daily." With a strong CYP3A4 inhibitor which blocks OATP1B as well, AVOID the combination outright: the label names ritonavir, and cobicistat inhibits OATP1B1/1B3 according to its own label. With a strong CYP3A4 inducer (the label's studied example is carbamazepine), AVOID. With a moderate inducer (the label's modeled example: efavirenz), the label asks your prescriber to keep checking that Foundayo still works and to step the dose up if it does not. Ask your pharmacist which group your drug is in. None of this reaches Wegovy, Ozempic, Mounjaro or Zepbound.

Mechanism

Orforglipron, an oral small-molecule GLP-1 receptor agonist, "is metabolized primarily via hepatic CYP3A4" and is also a substrate of the OATP1B1 and OATP1B3 transporters, which is why a drug that inhibits both raises exposure further. Inhibit CYP3A4 and exposure rises; induce it and exposure falls. The semaglutide and tirzepatide labels report low potential for CYP interactions and set no CYP3A4 dosing rule.

Source: Foundayo PI Section 7.1 (Table 2) and Section 2.2: "The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor. Avoid concomitant use of FOUNDAYO with strong CYP3A4 inhibitors that also inhibit OATP1B (e.g., ritonavir)"; "Avoid concomitant use of FOUNDAYO with strong CYP3A4 inducers"; "Monitor FOUNDAYO effectiveness and escalate dosage as needed when used concomitantly with moderate CYP3A4 inducers." Exposure data: Foundayo PI Section 12.3. Cobicistat OATP1B1/1B3 inhibition: TYBOST PI Section 7.1.

Warfarin

Anticoagulant

Moderate — be aware

Common brand names

Coumadin · Jantoven

Clinical effect

With the stomach emptying more slowly, warfarin may be absorbed at a different rate and INR may shift with it. In practice the effect is usually small, though it varies between people.

What to do

Step up INR monitoring whenever a GLP-1 receptor agonist is started or its dose raised. Changing the warfarin dose is rarely called for, but that call belongs to whoever manages your anticoagulation.

Mechanism

Gastric emptying slows under a GLP-1 receptor agonist. That can delay warfarin absorption while leaving total bioavailability broadly intact.

Source: Mounjaro PI Section 7.2 and Zepbound PI Section 7.2 name warfarin: "Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin)". Wegovy PI Section 7.2: "Consider increased clinical or laboratory monitoring for medications that have a narrow therapeutic index". Semaglutide PK studies found no clinically relevant change in S- or R-warfarin (Ozempic PI Section 12.3; Wegovy PI Section 12.3).

Oral contraceptives (combined and progestin-only)

Oral contraceptive

Moderate — be aware

Common brand names

Yasmin · Yaz · Loestrin · Lo Loestrin Fe · Microgestin · Sprintec · Tri-Sprintec · Ortho Tri-Cyclen · Necon · Junel · Mononessa · Camila · Errin · Slynd

Clinical effect

Where oral hormonal contraceptives are concerned the drugs part company. Tirzepatide's pharmacokinetic study found contraceptive exposure dropping after the first dose, so the Mounjaro and Zepbound labels carry an explicit FDA directive, and Foundayo (oral orforglipron) carries one of the same kind. Semaglutide does not: the Ozempic and Wegovy labels report NO clinically significant change in levonorgestrel or ethinyl estradiol pharmacokinetics, and no backup contraception is required with it.

What to do

Starting TIRZEPATIDE (Mounjaro or Zepbound) or FOUNDAYO while on oral birth control means following the FDA label: either move to a non-oral method — ring, patch, injection, implant, IUD — or add a barrier method on top. How long depends on the drug. On Foundayo the cover runs 30 days from the start, then a further 30 days from each dose increase. On tirzepatide it is 4 weeks from the start, and 4 weeks again from each dose increase. No such requirement attaches to semaglutide (Wegovy/Ozempic), though your contraception plan is still worth confirming with your prescriber.

Mechanism

Anything taken by mouth can be absorbed more slowly, or less completely, when gastric emptying slows. Tirzepatide's effect is measured and on the label: with a single 5 mg dose, ethinyl estradiol Cmax fell 59% and AUC 20%, and the label notes tirzepatide's effect on gastric emptying was greatest after the first dose and diminished after later ones. For Foundayo the label says its effect on oral contraceptives "has not been evaluated in a clinical trial", so the directive is a precaution. Semaglutide's labeled PK data show nothing clinically relevant. A hormonal contraceptive that is not swallowed is unaffected.

Source: Mounjaro PI Section 7.2; Zepbound PI Section 7.2 (barrier/non-oral for 4 weeks after initiation and each escalation; PK in Section 12.3); Foundayo PI Sections 7.3 and 8.3 (barrier/non-oral for 30 days after initiation and each escalation). Semaglutide: Ozempic PI Section 12.3 (ethinyl estradiol/levonorgestrel assessed at steady state, no clinically relevant drug-drug interaction) and Wegovy PI Section 12.3 (no clinically significant difference in ethinyl estradiol or levonorgestrel PK).

Levothyroxine (thyroid hormone replacement)

Thyroid hormone

Moderate — be aware

Common brand names

Synthroid · Levoxyl · Tirosint · Unithroid

Clinical effect

The Wegovy label, which now covers Wegovy tablets, reports that when levothyroxine was given with the semaglutide tablet in an interaction study, levothyroxine exposure rose by 33% (90% CI: 1.25-1.42). The injection studies found no effect on the oral drugs tested, but every GLP-1 label asks for caution with oral medications because gastric emptying slows.

What to do

Tell your prescriber you take levothyroxine before a GLP-1 starts, and expect your thyroid levels (TSH) to be rechecked after it starts or the dose changes. The Wegovy label says to "Monitor the effects of oral medications" and to consider increased laboratory monitoring for drugs that need it. On Wegovy tablets, the label says to wait at least 30 minutes after the tablet before taking other oral medications. Never change your levothyroxine dose on your own.

Mechanism

The labels put the oral-medication caution down to delayed gastric emptying. The 33% rise was measured with the semaglutide tablet; the labels report no such study with an injectable GLP-1.

Source: Wegovy PI Section 7.2 and 12.3 (levothyroxine exposure +33% with the semaglutide tablet; monitor oral medications) and Section 2.1 (wait at least 30 minutes after a Wegovy tablet before other oral medications); general oral-medication caution in Ozempic, Mounjaro and Zepbound PI Section 7.2 and Foundayo PI Section 7.3.

Opioid analgesics

Opioid analgesic

Moderate — be aware

Common brand names

OxyContin · Percocet · Vicodin · tramadol · Norco · Dilaudid · morphine · fentanyl patch · codeine

Clinical effect

Gut motility slows under opioids and under GLP-1 receptor agonists alike, and using both compounds the risk of fecal impaction, severe constipation and ileus. Every FDA-approved GLP-1 label lists those events in Section 6.2, Postmarketing Experience.

What to do

Keep the opioid at the lowest dose that works, and push fluid and fiber up. Four things mean stopping the GLP-1 and getting emergency care straight away: severe constant abdominal pain, persistent vomiting, abdominal distension, or >24 hours with no stool or gas.

Mechanism

Two distinct mechanisms slow motility and they compound: opioid μ-receptor effects on enteric neurons, and GLP-1 receptor agonism on the same neurons. It matters most through early titration, when the GLP-1 GI effects run highest.

Source: GLP-1 ileus / intestinal obstruction listed in Section 6.2 (Postmarketing Experience) of every FDA-approved GLP-1 label. No formal PK study of opioid + GLP-1 combination has been published; this is mechanism-based guidance resting on that FDA postmarketing signal.

Benzodiazepines (alprazolam, lorazepam)

Benzodiazepine

Moderate — be aware

Common brand names

Xanax · alprazolam · Ativan · lorazepam · Klonopin · clonazepam · Valium · diazepam · Restoril · temazepam

Clinical effect

Adipose tissue is where benzodiazepines distribute. Lose body weight on a GLP-1 and their volume of distribution can shift, which lets the same dose reach a higher effective plasma concentration. A 2025 review notes that lorazepam's volume of distribution was 1.7-fold lower in non-obese than in obese participants. That is a comparison between groups, not a measured weight-loss change.

What to do

Watch for morning grogginess, impaired balance and deeper sedation, most of all through the rapid-weight-loss phase in months 1-6. If any of that appears, raise a dose reduction with your prescriber — never make the change yourself.

Mechanism

These drugs are strongly lipophilic. Lose fat quickly and the compartment they distribute into shrinks; a smaller distribution volume means the same milligram dose sits at a higher relative plasma concentration.

Source: Review of GLP-1 receptor agonist pharmacokinetics and drug-drug interactions, Drug Des Devel Ther 2025 (PMC12052016), which proposes the weight-loss / volume-of-distribution mechanism and cites diazepam, lorazepam and nitrazepam data comparing obese and non-obese participants. No GLP-1-cohort PK study of benzodiazepines has been published; mechanism-plausible only.

Acetaminophen (paracetamol)

Analgesic / antipyretic

Minor — generally safe

Common brand names

Tylenol · Panadol · FeverAll

Clinical effect

Acetaminophen may take a little longer to start working. On the tirzepatide labels, a first 5 mg dose cut acetaminophen's peak level by 50-55% and pushed the peak back about 1 hour; by week 4 to 6 there was no meaningful effect, and total exposure (AUC) was not influenced. On the Foundayo label, the first 0.8 mg dose cut acetaminophen's peak by 28%, and the effect faded with repeated dosing.

What to do

Nothing to do differently. Take it as you always have; relief from pain or fever may simply arrive a little later.

Mechanism

Slower gastric emptying delays acetaminophen's peak. The tirzepatide labels report that the effect on gastric emptying was greatest after the first dose and diminished after later doses.

Source: Mounjaro PI Section 12.3 (Cmax -50%, tmax 1 hour later after the first dose; no meaningful impact at week 4; AUC not influenced); Zepbound PI Section 12.3 (Cmax -55%, tmax 1 hour later; no meaningful impact at week 6 on 15 mg; AUC not influenced). Foundayo PI Section 12.3 (Cmax -28% after the first 0.8 mg dose; the effect diminished with repeated 17.2 mg dosing). The semaglutide labels report no acetaminophen data; general oral-medication caution in Section 7.2 (Section 7.3 on Foundayo).

Metformin

Biguanide (oral diabetes medication)

Minor — generally safe

Common brand names

Glucophage · Glumetza · Fortamet · Riomet

Clinical effect

The pair is generally well tolerated. Both bring the same GI side effects — diarrhea, nausea — and in the opening weeks of GLP-1 therapy those can stack.

What to do

Stay on metformin as prescribed. Expect diarrhea and nausea to be temporarily worse while the GLP-1 dose is ramping. Neither drug usually needs its dose changed.

Mechanism

Two unrelated mechanisms. Metformin activates AMPK and cuts hepatic glucose production; the GLP-1 raises glucose-dependent insulin secretion. GI side effects arise from each on its own.

Source: Common combination, no specific FDA label warning

Statins (HMG-CoA reductase inhibitors)

Cholesterol medication

Minor — generally safe

Common brand names

Lipitor · atorvastatin · Crestor · rosuvastatin · Zocor · simvastatin · Pravachol · pravastatin · Mevacor · lovastatin

Clinical effect

None of the semaglutide or tirzepatide labels restricts a statin. Semaglutide PK studies found no clinically relevant change in atorvastatin (Ozempic label) or rosuvastatin (Wegovy label). FOUNDAYO (orforglipron) breaks the pattern: it doubled exposure of simvastatin's active form, simvastatin acid, and the label caps the simvastatin dose accordingly.

What to do

On semaglutide or tirzepatide, nothing changes: carry on with the statin as prescribed. On FOUNDAYO, simvastatin stops at 20 mg once daily and must go no higher; no other statin has a labeled dose limit. Confirm the dose with your prescriber as Foundayo starts.

Mechanism

Foundayo acts on the other drug: "Use of FOUNDAYO with simvastatin increased exposure of the active metabolite simvastatin acid two-fold", which "at the highest simvastatin dose could be clinically meaningful." The Foundayo label also reports smaller rises for atorvastatin (AUC 1.5-fold) and rosuvastatin (1.7-fold) but sets no dose rule for them.

Source: Semaglutide: Ozempic PI Section 12.3 (atorvastatin, no clinically relevant drug-drug interaction); Wegovy PI Section 12.3 (rosuvastatin, no clinically significant PK difference). Tirzepatide labels: no statin statement. Foundayo PI Section 7.2 (Table 3): "Do not exceed simvastatin 20 mg once daily when concomitantly used with FOUNDAYO." Atorvastatin/rosuvastatin exposure: Foundayo PI Section 12.3.

ACE inhibitors and ARBs (blood pressure medications)

Blood pressure medication

Minor — generally safe

Common brand names

Lisinopril · Zestril · Prinivil · losartan · Cozaar · valsartan · Diovan · irbesartan · Avapro · olmesartan · Benicar

Clinical effect

No interaction as such. The GLP-1-induced weight loss tends to bring blood pressure down a little on its own, and that adds to whatever the antihypertensive is already doing.

What to do

Keep taking your blood pressure medication as prescribed, but watch for the signs of it running too low — lightheadedness when you stand. As the weight comes off, the dose may need reducing.

Mechanism

Blood pressure falls with weight loss on its own account. Stack that on antihypertensive therapy and hypotension is an occasional result.

Source: Common combination, no specific FDA label warning

SSRIs, SNRIs and bupropion (antidepressants)

Antidepressant

Minor — generally safe

Common brand names

Lexapro · escitalopram · Zoloft · sertraline · Prozac · fluoxetine · Paxil · paroxetine · Cymbalta · duloxetine · Effexor · venlafaxine · Wellbutrin · bupropion

Clinical effect

No drug interaction as such. The EMA's safety committee (PRAC) found in April 2024 that the evidence on semaglutide, liraglutide, dulaglutide, exenatide and lixisenatide did not support a causal link with suicidal or self-harm thoughts and actions, and in February 2026 the warning on Suicidal Behavior and Ideation came off both the Wegovy label and the Zepbound label.

What to do

Stay on the antidepressant as prescribed. Where there is a history of depression, keep active track of mood through the first 8-12 weeks on a GLP-1, and take anything that shifts to your mental health provider as well as your prescriber.

Mechanism

The mechanisms are unrelated, and no pharmacokinetic interaction has been documented.

Source: EMA PRAC meeting highlights, April 8-11, 2024; Wegovy PI and Zepbound PI Recent Major Changes: Suicidal Behavior and Ideation warning (Removed) 02/2026.

PPIs and H2 blockers (acid reflux medications)

Acid suppression

Minor — generally safe

Common brand names

Prilosec · omeprazole · Nexium · esomeprazole · Protonix · pantoprazole · Pepcid · famotidine · Zantac

Clinical effect

No drug interaction as such, and the pairing may work in your favor: acid reflux is something a GLP-1 receptor agonist can bring on or aggravate, and managing it is exactly what PPIs/H2 blockers do.

What to do

Carry on with it, or start it, as reflux symptoms require. Take reflux that is severe or will not settle to your prescriber.

Mechanism

GERD can worsen under GLP-1-induced slowing of gastric emptying; suppressing acid treats the symptom that results.

Source: No specific FDA label warning

NSAIDs (ibuprofen, naproxen, celecoxib)

Non-steroidal anti-inflammatory drug (NSAID)

Minor — generally safe

Common brand names

Advil · Motrin · ibuprofen · Aleve · naproxen · Celebrex · celecoxib · Mobic · meloxicam

Clinical effect

Slowed gastric emptying may delay NSAID absorption, so pain relief can start later. We found no study that has measured NSAID levels with any GLP-1; this rests on the labels' general caution about oral medications.

What to do

Take it as prescribed, and keep an eye out for NSAID-related GI effects that seem out of the ordinary — during titration they add to what the GLP-1 is already doing. Ongoing pain that needs an NSAID is worth a conversation with your prescriber about dose and timing.

Mechanism

The absorption of an NSAID taken by mouth can shift when gastric emptying is delayed. How much, if at all, has not been measured.

Source: General oral-medication caution: Section 7.2 of the Wegovy, Ozempic, Mounjaro and Zepbound labels; Section 7.3 of the Foundayo label. No GLP-1 PK study of NSAIDs has been published; mechanism-plausible only. (A 2025 PBPK modeling study, Hooper et al, Pharmacotherapy, PMID 39989027, did not model NSAIDs and predicted AUC increases for some other oral drugs.)

Oral antibiotics

Oral antibiotic

Minor — generally safe

Common brand names

amoxicillin · Augmentin · azithromycin · Z-Pak · doxycycline · ciprofloxacin · Cipro · clindamycin · cephalexin · Keflex

Clinical effect

The rate at which an oral antibiotic is absorbed can change under GLP-1-induced gastric emptying delay. No study has measured how much; with some agents, onset may simply arrive later.

What to do

Take it as prescribed and finish the course. Should vomiting or severe nausea on the GLP-1 stop you keeping doses down, tell your prescriber promptly: an underdosed antibiotic invites antimicrobial resistance and treatment failure.

Mechanism

Every GLP-1 label carries a class-level caution (Section 7.2; Section 7.3 on Foundayo) covering any oral medication given alongside a drug that delays gastric emptying. No PK study specific to antibiotics has been published.

Source: Section 7.2 of the Wegovy, Ozempic, Mounjaro and Zepbound labels and Section 7.3 of the Foundayo label (general oral-medication caution). No formal PK study of any specific antibiotic + GLP-1 combination has been published; class-level mechanism-based guidance only.

Atypical antipsychotics (olanzapine, quetiapine)

Atypical antipsychotic

Minor — generally safe

Common brand names

Zyprexa · olanzapine · Seroquel · quetiapine · Risperdal · risperidone · Abilify · aripiprazole · Clozaril · clozapine

Clinical effect

For anyone on long-term antipsychotic therapy, a GLP-1 receptor agonist works against the weight gain those drugs cause. Several systematic reviews back the combination, and nobody has reported a pharmacokinetic interaction between the two that matters clinically.

What to do

Stay on both, supervised by your prescriber. Antipsychotic efficacy is not reduced by the GLP-1, which meanwhile blunts the weight gain. Keep the prescribing psychiatrist or PCP in the loop.

Mechanism

What the GLP-1 does to appetite and gastric emptying runs against the appetite stimulation and weight gain of an atypical antipsychotic. Different physiological pathways, and no pharmacokinetic interference between them.

Source: Systematic reviews PMC10265718 + PMC12528064 on GLP-1 receptor agonists in antipsychotic-induced weight gain. No clinically significant DDI documented; mechanism-supported beneficial combination.

How to read the severity tiers

  • Contraindicated — Do not combine. The combination is explicitly contraindicated by the FDA label. No entry in the database sits in this tier at present; combining two GLP-1 receptor agonists, which the Wegovy, Zepbound and Foundayo labels call “not recommended”, is listed as Serious.
  • Serious — you may combine them, but only with close monitoring, or with one drug's dose adjusted in advance. Insulin and the sulfonylureas are the standard case: both can drive hypoglycemia, so the labels tell prescribers to consider lowering the existing diabetes medication when the GLP-1 starts.
  • Moderate — Be aware. The interaction is real but usually does not require dose adjustment. Often involves slowed gastric emptying changing how an oral medication is absorbed; sometimes total exposure shifts too (levothyroxine rose 33% with the semaglutide tablet). Examples: warfarin, levothyroxine, oral contraceptives.
  • Minor — Generally no action needed. Either no documented interaction or the effect is clinically irrelevant (e.g., the roughly 1-hour delay in acetaminophen's peak after a first tirzepatide dose).

Why GLP-1s have so many gastric-emptying interactions

GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action — that's a major contributor to the satiety effect that produces weight loss. The same mechanism can delay the absorption of medications taken by mouth, which is why every one of these labels asks for caution with oral medications. In the labeled studies the effect was usually small: after a first tirzepatide dose, acetaminophen peaked about 1 hour later with total exposure (AUC) unchanged, and semaglutide injection did not affect the oral drugs tested to any clinically relevant degree. Exceptions exist: levothyroxine exposure rose 33% with the semaglutide tablet, and tirzepatide lowered oral contraceptive levels. The labels ask for closer monitoring of drugs with a narrow therapeutic index, such as warfarin.

Hypoglycemia risk with insulin and sulfonylureas

The most clinically important GLP-1 interaction is the additive hypoglycemia risk when combined with insulin or a sulfonylurea (glipizide, glyburide, glimepiride). GLP-1s enhance glucose-dependent insulin secretion — meaning they only push insulin when blood sugar is elevated — but adding insulin or a sulfonylurea on top can produce dangerous lows. Every one of the five labels tells prescribers to consider reducing the dose of insulin or the insulin secretagogue when the GLP-1 is started. The labels set no fixed percentage, so the size of the cut is your prescriber's call. Discuss it with them before the first GLP-1 dose, not after the fact.

Oral contraceptives: a labeled warning on Foundayo and on tirzepatide

Which GLP-1 you are on decides what the FDA label asks of you here.Tirzepatide (Mounjaro and Zepbound) carries an explicit Section 7 directive: move to a non-oral method — ring, patch, injection, implant or IUD — or add a barrier method, holding that for 4 weeks from the start, then 4 weeks from every dose increase. Foundayo (orforglipron, the oral GLP-1) asks the same thing on a longer clock: 30 days from the start, and 30 days from every dose increase. Semaglutide (Wegovy and Ozempic) is the exception — its label reports no clinically significant change in oral contraceptive (ethinyl estradiol/levonorgestrel) levels, so it does not require backup contraception. The tirzepatide and Foundayo labels say hormonal contraceptives not taken by mouth should not be affected. If you take oral birth control and are starting tirzepatide or Foundayo, discuss a backup strategy with your prescriber before your first dose.

What this tool is NOT

It is a lookup tool for learning from, and nothing more. It is not clinical decision support, not a replacement for your pharmacist or prescriber, and not the real-time checker built into an electronic health record. What the database holds are the clinically meaningful interactions that come up most often — not all of them. Tell every pharmacist and every prescriber everything you take, supplements and over-the-counter products included, and check any specific interaction with them before you start or stop anything.

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) injection and tablets — US Prescribing Information, Recent Major Changes and Sections 1, 2.1, 5.4, 6.2, 7 and 12.3. DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b, SPL version 19 (published June 30, 2026). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Novo Nordisk Inc. OZEMPIC (semaglutide) injection — US Prescribing Information, Sections 6.2, 7 and 12.3. DailyMed SetID adec4fd2-6858-4c99-91d4-531f5f2a2d79, SPL version 20 (published June 10, 2026). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  3. 3.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Recent Major Changes and Sections 1, 5.7, 6.2, 7 and 12.3. DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b, SPL version 40 (published September 2, 2026). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  4. 4.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — US Prescribing Information, Sections 6.2, 7 and 12.3. DailyMed SetID d2d7da5d-ad07-4228-955f-cf7e355c8cc0, SPL version 40 (published September 2, 2026). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  5. 5.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information, Sections 1, 2.2, 5.5, 6.2, 7, 8.3 and 12.3. DailyMed SetID 8ac446c5-feba-474f-a103-23facb9b5c62, SPL version 10 (published August 13, 2026). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  6. 6.Gilead Sciences, Inc. TYBOST (cobicistat) tablets — US Prescribing Information, Section 7.1 (transporters inhibited, including OATP1B1 and OATP1B3). DailyMed SetID 3784c35c-e87f-410c-900b-8fd6313c6010, SPL version 16 (published February 18, 2026). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3784c35c-e87f-410c-900b-8fd6313c6010
  7. 7.Hooper L, Liu S, Pai MP. GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis. Pharmacotherapy. 2025. PMID: 39989027.
  8. 8.Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, Bae SK. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist. Drug Design, Development and Therapy. 2025. PMID: 40330819.
  9. 9.European Medicines Agency, Pharmacovigilance Risk Assessment Committee (PRAC). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) April 8-11, 2024: GLP-1 receptor agonists, available evidence not supporting link with suicidal and self-injurious thoughts and actions. EMA. 2024. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024

Important disclaimer

Educational material, not medical advice. What an interaction does to you turns on your dose, your timing and everything else on your medication list, which makes it an individual matter. GLP Watchdog gives no diagnosis, no treatment recommendation and no medical advice. Before any medication joins a GLP-1 receptor agonist, put it to your pharmacist and your prescribing clinician.

Alcohol has its own write-up, drinking on a GLP-1, built from the same labels.

Data freshnessLast verified Cadence: quarterly

Source: Recent Major Changes and Sections 1, 2, 5, 6.2, 7, 8 and 12.3 of the current Wegovy, Ozempic, Mounjaro, Zepbound and Foundayo prescribing information on DailyMed, re-read October 24-25, 2026, plus the Tybost label, two peer-reviewed papers and the EMA's April 2024 safety review for entries no GLP-1 label covers. General clinical guidance that no label states (thyroid-test timing, blood-pressure dose changes, switching between drugs) is marked as advice to confirm with a pharmacist.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.4

Wellorithm

Compounded semaglutide at a flat $247 every 28 days, any dose

8.5

Gala

Moving between compounded and brand without changing seller

7.9

Luvo Health

Moving between compounded and brand without changing seller